Related Experiment Video
Updated: Jul 27, 2026
Bioluminescence Imaging of NADPH Oxidase Activity in Different Animal Models
Published on: October 22, 2012
Molybdenum Nanoparticles Alleviate MC903-Induced Atopic Dermatitis-Like Symptoms in Mice by Modulating the
Qin Xiao1, Jing Guo1, Yongzhou Lu1
1Department of Dermatology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China.
Purpose:
Atopic dermatitis (AD) is a chronic inflammatory skin condition that can affect individuals of all ages. Recent research has shown that oxidative stress plays a crucial role in the development of AD. Therefore, inhibiting oxidative stress may be an effective therapeutic approach for AD. Nano-molybdenum is a promising material for use as an antioxidant. We aimed to evaluate the therapeutic effects and preliminary mechanisms of molybdenum nanoparticles (Mo NPs) by using a murine model of chemically induced AD-like disease.
Methods:
HaCaT cells, a spontaneously immortalized human keratinocyte cell line, were stimulated by tumor necrosis factor-alpha /interferon-gamma after pre-treatment with Mo NPs. Reactive oxygen species levels, production of inflammatory factors, and activation of the nuclear factor kappa-B and the nuclear factor erythroid 2-related factor pathways were then evaluated. Mo NPs was topically applied to treat a murine model of AD-like disease induced by MC903, a vitamin D3 analog. Dermatitis scores, pruritus scores, transepidermal water loss and body weight were evaluated. AD-related inflammatory factors and chemokines were evaluated. Activation of the nuclear factor kappa-B and nuclear factor erythroid 2-related factor / heme oxygenase-1 pathways was assessed.
Results:
Our data showed that the topical application of Mo NPs dispersion could significantly alleviate AD skin lesions and itching and promote skin barrier repair. Further mechanistic experiments revealed that Mo NPs could inhibit the excessive activation of the nuclear factor kappa-B pathway, promote the expression of nuclear factor erythroid 2-related factor and heme oxygenase-1 proteins, and suppress oxidative stress reactions. Additionally, they inhibited the expression of thymic stromal lymphopoietin, inflammatory factors, and chemokines, thereby alleviating skin inflammation.
Conclusion:
Mo NPs present a promising alternative treatment option for patients with AD as they could address three pivotal mechanisms in the pathogenesis of AD concurrently.
Insights
Molybdenum nanoparticles (Mo NPs) effectively treat atopic dermatitis (AD) by reducing inflammation and oxidative stress. This study shows Mo NPs alleviate AD symptoms and repair skin barriers in a mouse model.
Area of Science:
- Dermatology
- Nanotechnology
- Biochemistry
Background:
- Atopic dermatitis (AD) is a chronic inflammatory skin condition.
- Oxidative stress is a key factor in AD development.
- Nano-molybdenum shows potential as an antioxidant therapy.
Purpose of the Study:
- To evaluate the therapeutic effects of molybdenum nanoparticles (Mo NPs) on AD.
- To investigate the preliminary mechanisms of Mo NPs in a murine model of AD-like disease.
Main Methods:
- HaCaT cells were used to assess Mo NP effects on inflammatory markers and pathways.
- A mouse model of chemically induced AD-like disease was treated with topical Mo NPs.
- Evaluated dermatitis and pruritus scores, skin barrier function, and inflammatory markers.
Main Results:
- Topical Mo NPs significantly reduced AD skin lesions, itching, and improved skin barrier repair.
- Mo NPs inhibited the nuclear factor kappa-B pathway and suppressed oxidative stress.
- Mo NPs reduced inflammatory factors, chemokines, and thymic stromal lymphopoietin expression.
Conclusions:
- Mo NPs offer a promising therapeutic option for atopic dermatitis.
- Mo NPs concurrently target multiple key mechanisms in AD pathogenesis.
- This suggests a novel approach for managing AD symptoms and underlying causes.
